Home Blog Page 94

Laos, Thailand Move Luang Prabang Bridge Toward Construction

Laos and Thailand advance an 820-meter Luang Prabang bridge project after completing key studies, approving designs, and preparing the loan agreement.

Laos and Thailand have moved a planned 820-meter bridge in Luang Prabang Province into the next stage of development, with the project’s environmental and social impact assessment and detailed design now complete and construction expected to begin in 2027.

The two sides exchanged project documents and inspected the planned bridge site on 2 October during the 23rd Lao-Thai Cooperation Committee meeting in Luang Prabang.

Lao Deputy Prime Minister and Foreign Minister Thongsavanh Phomvihane and his Thai counterpart Sihasak Phuangketkeow attended the meeting and witnessed the document exchange for the Xiengman-Luang Prabang bridge project.

The project had previously been awaiting financing. Thailand approved THB 1.78 billion (USD 55.4 million) in financial assistance for the bridge in September through the Neighbouring Countries Economic Development Cooperation Agency.

Laos and Thailand have now negotiated the concessional loan, with Laos preparing to sign the formal loan agreement.

The project began with a memorandum signed in January 2020 for a feasibility study and detailed design. The survey was delayed until 2022 due to the COVID-19 pandemic.

The Ministry of Public Works and Transport said the environmental and social impact assessment has since been completed and the detailed design approved.

Bridge Details

The bridge will connect Chomphet District with Luang Prabang Town, crossing the Mekong River.

It will be 820 meters long and 21.6 meters wide, with five box-girder spans. The central section will be 120 meters long and 15 meters above the river to allow boats to pass underneath.

A 14-kilometer connecting road will link the two ends of the bridge.

Construction is expected to take four years, followed by seven years of operation and maintenance under an Output and Performance-Based Contract.

The bridge is now targeted to open in 2031.

Linking Luang Prabang to Thailand

The bridge is expected to strengthen road connections between Luang Prabang and the Xayabouly-Thailand border corridor.

Chomphet is the only district in Luang Prabang Province located on the opposite bank of the Mekong from Luang Prabang town. It borders Xayabouly, which connects onward to Thailand’s Nan Province.

The bridge is expected to reduce travel time between Nan and Luang Prabang by around 30 to 45 minutes from the current journey of roughly nine hours.

The project is part of a broader Lao-Thai infrastructure cooperation plan that includes connecting the Laos-China railway with Thailand’s rail network and developing Lao-Thai friendship bridges.

Sovereign Wealth Fund Institute announces first I20 Summit alongside G20 Leaders’ Summit, targets US$5tn capital deployment into US

  • Five-day event set for Miami (11–15 December 2026) alongside the G20 Leaders’ Summit at Trump National Doral.
  • Convenes global sovereign, pension, and institutional allocators representing every G20 and allied nation.
  • SWFI targets US$5 trillion in capital deployment into key American growth sectors.

NEW DELHI, Oct. 5, 2026 /PRNewswire/ — The Sovereign Wealth Fund Institute (SWFI) has officially announced G20 Investment Week and the inaugural I20 Summit, taking place in Miami from 11–15 December 2026. Held alongside the official G20 Leaders’ Summit at Trump National Doral, this invitation-only gathering aims to direct US$5 trillion in long-term institutional capital into the United States.

Lakshmi Narayanan Ramanujam, SWFI Chairman, Chip Rogers, Advisor and spokesperson to SWFI, and Michael Maduell, SWFI President and CEO announce G20 Investment Week at iBRICS 2026, The Oberoi, New Delhi. Photo: SWFI.
Lakshmi Narayanan Ramanujam, SWFI Chairman, Chip Rogers, Advisor and spokesperson to SWFI, and Michael Maduell, SWFI President and CEO announce G20 Investment Week at iBRICS 2026, The Oberoi, New Delhi. Photo: SWFI.

The five-day program opens with a welcome dinner on 11 December, followed by specialized investor days, and concludes on 15 December with Global Leaders Day and the GOOD Fellows Awards. Over three core days, SWFI will host parallel sector sessions bringing sovereign wealth funds, pension funds, endowments, central bank reserve managers, and state officials into direct alignment. American governors and economic development authorities will present shovel-ready projects across twelve key growth sectors, including energy & LNG, SI & data center infrastructure, critical minerals, advanced manufacturing, real estate, private credit, and digital assets.

Announced at iBRICS 2026 in New Delhi, the initiative engages allocators across the Global South and allied economies spanning G20 members, the European Union, the African Union, and invited guest nations such as Qatar, Singapore, the UAE, Norway, and Finland.

Lakshmi Narayanan Ramanujam, Chairman, SWFI said: “The G20 sets the direction of the world economy. The I20 is where capital decides whether to follow. We unveiled this project at iBRICS 2026 in New Delhi because capital does not belong to a bloc. It looks for scale, rule of law and returns, and no market offers more of all three than the United States.”

Chip Rogers, Advisor and spokesperson to SWFI, said: “American states have projects that are permitted and ready for capital. What they rarely get is a week in the same city as the funds that can finance them. Miami gives them that week.”

About the I20 Summit

The I20 Summit is SWFI’s independent convening of long-term investors for the United States’ G20 host year. https://i20summit.com/

About the Sovereign Wealth Fund Institute

Established in 2008 and headquartered in Dallas, Texas, SWFI has convened sovereign wealth funds, pension funds and family offices across 60 cities in 20 countries, at venues including the House of Commons, Guildhall and Mansion House. www.swfinstitute.org

E&R Engineering to Launch New Malaysia Plant: Expanding Global Packaging Materials Production and Localized Services

KAOHSIUNG, Oct. 5, 2026 /PRNewswire/ — E&R Engineering Corp., (TWSE: 8027) an international provider of semiconductor packaging equipment, announced today the upcoming grand opening of its new Malaysian subsidiary—E&R SEMICONDUCTOR (MALAYSIA) SDN. BHD.—at the Melaka Free Trade Zone on October 13.

E&R Engineering Opens New Malaysia Plant to Strengthen Semiconductor Packaging Support
E&R Engineering Opens New Malaysia Plant to Strengthen Semiconductor Packaging Support

To meet surging Southeast Asian demand, E&R Engineering is upgrading its global strategy for the packaging materials business unit. While its plant in China continues to experience steady business growth, E&R is strategically shifting a portion of its production focus to Malaysia while expanding overall capacity. The new facility is currently undergoing sample testing and qualification, with mass production scheduled to begin early next year. The plant is expected to create 50 local job opportunities and strengthen E&R’s supply capabilities for semiconductor and OSAT customers in Southeast Asia.

Deepening Roots in Southeast Asia’s Packaging Hub: Localized Mass Production of Advanced Carrier Tapes

Accounting for approximately 13% of the world’s backend packaging and testing capacity, Malaysia’s semiconductor market is projected to reach $16.51 billion by 2030, driven by robust policy support. Capitalizing on this momentum and increasing regional customer demand, E&R has established a footprint in Phase III of the Batu Berendam Free Trade Zone in Melaka. The facility brings its manufacturing expertise in high-end Embossed Carrier Tapes and Cover Tapes directly to local production.

Through “local manufacturing and fast response,” the new plant directly addresses the needs of OSAT and semiconductor customers—shortening lead times while providing high precision, excellent electrostatic discharge (ESD) protection, and robust packaging interfaces to support advanced packaging trends such as chip miniaturization and Chiplet integration.

Opening a New Chapter with “Innovation, Collaboration, and Growth”

E&R President KS Chen stated: “To address growing customer demand in Southeast Asia, we have shifted part of our production focus for packaging materials to Malaysia while expanding capacity. Furthermore, this facility serves as a local hub for E&R’s semiconductor equipment Field Service Engineers. We will focus on hiring local talent and building our specialized equipment engineering team, enabling us to provide immediate, localized technical support and after-sales services.”

AK Ong, General Manager of the Malaysia plant, added: “The completion of our new facility allows us to stay closer to our customers, offering real-time support. We remain committed to delivering top-quality products and strictly monitoring every quality checkpoint to create a win-win future for all.”

E&R Website: https://en.enr.com.tw/

FGR advances carbon fibre commercialisation with Aeropreg agreement

Highlights

  • First Graphene enters Development and Commercialisation Agreement with global prepreg manufacturer Aeropreg to develop graphene-enhanced carbon fibre prepreg
  • Three-year agreement builds on positive results from First Graphene’s development work incorporating PureGRAPH® into carbon fibre composites
  • Collaboration combines PureGRAPH® and proprietary epoxy concentrates with Aeropreg’s established manufacturing and resin development capabilities
  • First Graphene intends to progress the graphene-enhanced prepreg product towards commercial launch through Aeropreg’s existing sales channels
  • Partnership solidifies FGR’s pathway into the global carbon fibre reinforced plastics market, estimated to grow to US$43.7 billion by 2033

SYDNEY, Oct. 5, 2026 /PRNewswire/ — First Graphene Limited (ASX: FGR; “First Graphene” or “the Company”) (FRA:M11) (OTCQB:FGPHF) has entered a three-year Development and Commercialisation Agreement with Turkish prepreg manufacturer, Aeropreg, to advance a PureGRAPH® enhanced carbon fibre prepreg towards commercialisation.

Under the three-year agreement, First Graphene’s proprietary epoxy concentrates will be used to optimise the incorporation of PureGRAPH® into Aeropreg’s existing carbon fibre prepreg manufacturing process.

Carbon fibre prepreg is a composite material that has been pre-infused with partially cured polymer resin and is often used to strengthen components used in aerospace, defence, automotives and sporting goods.

The development program will focus on achieving controlled and repeatable graphene loading within prepreg before validating the strength, durability, performance and manufacturability of the resulting material.

Subject to trial results, First Graphene and Aeropreg will advance the material towards commercial launch, leveraging Aeropreg’s existing sales channels across the aerospace, automotive, marine and sporting goods industries.

The new partnership represents the next stage in First Graphene’s strategy to convert its technical development in carbon fibre composites into commercial opportunities for PureGRAPH®.

It also follows First Graphene’s track record of positive results from customer development programs and grant-funded research on graphene-enhanced carbon fibre composites.

Securing a commercial prepreg solution and an experienced manufacturing partner is an essential step towards addressing defence, aerospace and automotive applications. Modern commercial aircraft make extensive use of carbon fibre prepreg in their airframes, for primary structures.

The collaboration aligns with First Graphene’s increased focus on the US market and its recent acquisition of MITO Materials, which expanded the Company’s composites technology and customer relationships in North America.

Importantly, Aeropreg has in-house resin development and testing capabilities, providing First Graphene with a manufacturing partner to advance this technology towards commercial production.

This agreement provides First Graphene with a potential pathway into the global carbon fibre reinforced plastics market, which is estimated to grow to the value of US$43.7 billion by 2033[1].

About Aeropreg

Aeropreg manufactures and supplies prepreg composite materials, including carbon, glass, aramid and basalt fibre prepregs, for aerospace, automotive, marine, sporting goods, medical and wind energy applications. The company offers customised material solutions and technical support to meet customers’ specific requirements.

Aeropreg’s research and development capabilities include developing and refining resin systems, supported by in-house chemical, physical, thermal and mechanical testing.

Aeropreg is a subsidiary of Spinteks. According to Aeropreg, its prepreg production operates under AS9100 aerospace quality management certification. In June 2026, Spinteks was added to the Turkish Aerospace (TUSAŞ) Approved Supplier List for composite manufacturing, with Aeropreg carrying out prepreg production within the group.[2]

First Graphene Managing Director and CEO, Michael Bell, said:

“The new partnership with Aeropreg represents an important step in progressing our carbon fibre development work towards commercialisation in key industries such as aerospace and defence.

We have built considerable knowledge around incorporating PureGRAPH® into composite materials and the next step was to combine that expertise with an established manufacturer capable of producing and taking a product to market.

Aeropreg brings extensive prepreg manufacturing and resin development capabilities, as well as established global sales channels across a number of high-value industries.

Our immediate focus will be on successfully validating the material within Aeropreg’s manufacturing process, with the longer-term objective of establishing another commercial route to market for PureGRAPH®.”

-Ends-

This announcement has been approved by the Chairman.

References

 

Tigerair Taiwan Expands Its Network With New Connected Travel Platform, Powered by Dohop

With Scoot as its first airline partner, tigerhop expands Dohop’s footprint in Asia and adds new network capacity and destinations for Taiwan’s leading low-cost carrier.

REYKJAVÍK, Iceland, Oct. 5, 2026 /PRNewswire/ — Dohop, the travel technology company creating a new standard for Connected Travel that works beyond traditional interline, has announced a new partnership with Tigerair Taiwan to deploy the Dohop-powered tigerhop platform, now live on the airline’s retail channels. Through the initial partnership with Scoot, Singapore Airlines’ low-cost subsidiary, Tigerair Taiwan customers will have more options for travel within Asia, specifically across North Asia routes and new connections to Singapore, all bookable in a single transaction.

Tigerair Taiwan Launches tigerhop, a Dohop-powered Connected Travel Platform
Tigerair Taiwan Launches tigerhop, a Dohop-powered Connected Travel Platform

Tigerhop, powered by Dohop’s RetailConnect platform, allows Tigerair Taiwan to sell multi-carrier journeys that combine its own flights with onward services operated by partner airlines. At launch, tigerhop will offer connections from Taipei and Da Nang to Singapore via Scoot, and travelers departing from Singapore can transfer at Taoyuan International Airport to other destinations, including Akita, Hanamaki, and Tottori.

“Tigerair Taiwan demonstrates how airlines can use Connected Travel to expand their network without the cost and complexity of bilateral interlining,” said Hugh Aitken, Chief Operating Officer at Dohop. “Launching tigerhop with Scoot gives Taiwanese travellers access to more destinations through Tigerair Taiwan’s own channels, while enabling the airline to capture bookings that might otherwise go to OTAs. With additional carriers joining the platform in the coming months, tigerhop also marks an important expansion of Dohop’s presence in Asia.”

For Tigerair Taiwan, the partnership adds connections with other carriers without complex interline or codeshare agreements, expanding its commercial reach with minimal technical investment. By selling these itineraries through tigerhop under its own brand, the airline can compete more effectively with online travel agents while giving passengers access to Dohop’s ConnectSure disruption support and travel protection services.

“Working with Dohop, we can grow our international reach without traditional interline structures while maintaining our brand promise to our passengers,” said Joyce Huang, Chairperson of Tigerair Taiwan. “We look forward to partnering with new carriers and expanding our coverage in the APAC region through Dohop’s technology.”

The Tigerair Taiwan launch extends Dohop’s presence across Asia, where its platforms are already live for Scoot, Thai Vietjet, Citilink and Air India Express, with others in development. These deployments reflect growing demand among Asian carriers for flexible connectivity that can integrate into existing retail channels without individual codeshare or bilateral interline agreements, supporting the industry’s broader move toward modular, multi-carrier connectivity and modern retailing.

For more information about the partnership between Dohop and Tigerair Taiwan, or to arrange an interview with a Dohop executive, please contact Vanessa Horwell at vhorwell@thinkinkpr.com.

About Dohop 
Dohop enables connected journeys from booking through arrival, combining flights and travel segments from multiple airlines and travel providers into a single trip supported by disruption handling, travel protection, and baggage transfer. More than 100 airlines and travel partners, including Air France, Air Transat, easyJet, Scoot, Vueling and Wizz Air, use Dohop’s Connected Travel platform to create, sell, and support multi-carrier journeys without traditional interline agreements, expanding network connectivity and route options as participation grows. Visit www.dohop.com/airlines to learn more.

About Tigerair Taiwan
Tigerair Taiwan launched its first route in 2014. As Taiwan’s first and only low-cost carrier (LCC), it operates routes across Asia, providing travelers with affordable, reliable, and convenient options. Focusing on a warm, passionate, and genuine service while upholding safety as its core value, Tigerair Taiwan continues to expand its footprint and add more destinations in Asia. Learn more at www.tigerairtw.com.

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared

MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ — CSL and Alentis Therapeutics today announced they have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.

Lixudebart is currently being evaluated in the ongoing Phase 2 RENAL trial in patients with ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), a rare and potentially life-threatening autoimmune disease that can cause irreversible kidney damage and end-stage renal disease.

With a novel mechanism of action, lixudebart exerts potent anti-inflammatory and anti-fibrotic effects to potentially prevent and reverse organ damage in ANCA-associated vasculitis (AAV) and numerous other kidney, liver and lung diseases. The ongoing phase 2 trial is designed to translate these mechanistic effects into meaningful clinical impact.  

The collaboration brings together Alentis’ scientific expertise as the leading clinical-stage biopharmaceutical company targeting claudin-1 and CSL’s global development and commercialisation capabilities in nephrology, with a shared goal of bringing innovative and highly impactful treatment options to patients with rare kidney and liver diseases. In addition to AAV-RPGN, the two companies will advance lixudebart as a novel treatment for focal segmental glomerulosclerosis (FSGS), a rare progressive kidney disease, and for primary sclerosing cholangitis (PSC), an autoimmune chronic liver disease.

“This partnership enables us to dramatically accelerate the development of lixudebart in several indications in parallel,” said Dr Mark Pruzanski, Chief Executive Officer of Alentis Therapeutics. “We are convinced CSL’s demonstrated clinical development and commercialisation capabilities in AAV and kidney diseases makes them the right partner to bring lixudebart to patients. More broadly, this furthers the validation of claudin-1 as a novel therapeutic target and we are excited about the potential to accelerate the advancement of our other clinical stage assets and preclinical pipeline.”

“Patients diagnosed with ANCA-associated vasculitis with rapidly progressive glomerulonephritis face rapid kidney function decline, leaving them at risk of irreversible damage even with currently available treatments,” said Dr Bill Mezzanotte, EVP, Head of R&D, CSL. “We believe lixudebart has the potential to become an important new therapeutic option to help improve kidney function and prevent progression to end-stage kidney disease, first in AAV-RPGN and hopefully also in focal segmental glomerulosclerosis, while potentially showing similar benefit on liver function in primary sclerosing cholangitis. Our partnership with Alentis reflects CSL’s commitment to building a leading global nephrology franchise, and our strategic intent to create high-value external partnerships.”

Under the agreement, CSL and Alentis will jointly develop and co-promote lixudebart. CSL will make an initial payment to Alentis of US$355 million, with Alentis eligible to receive up to an additional US$1.2 billion in commercial milestone payments. In addition to these payments, CSL will fully fund the completion of the ongoing Phase 2 RENAL trial and planned Phase 3 trial in AAV-RPGN, the Phase 2 trials in FSGS and PSC and other supporting development activities. Once commercialised, global profits will be shared 55 per cent to CSL and 45 per cent to Alentis.

About AAV-RPGN
ANCA (antineutrophil cytoplasmic antibodies)-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN) is a rare, severe and potentially fatal autoimmune disease in which the body’s immune system attacks small blood vessels in the kidney. RPGN is characterized by rapid loss of kidney function over a very short period (days to weeks). Despite potent immunosuppressive treatment, most patients develop significant or total loss of kidney function.

About Lixudebart
Lixudebart (formerly known as ALE.F02) is an investigational monoclonal antibody that selectively targets exposed claudin-1, a key driver of inflammatory and fibrotic signalling pathways in numerous fibrotic diseases of the kidney, liver, lung, intestine and other solid organs. In an interim analysis of 26 patients with AAV-RPGN in the ongoing Phase 2 RENAL trial, lixudebart showed promising improvement in kidney function as assessed by eGFR and proteinuria at 24 weeks. In the Phase 1b FEGATO trial in 41 patients with advanced F3/F4 liver fibrosis, lixudebart demonstrated improved liver function at 6 weeks. In both studies lixudebart showed dose-dependent claudin-1 target engagement, along with a favourable safety and tolerability profile. Lixudebart has been granted Orphan Drug designation by the FDA for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses, CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs almost 29,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

About Alentis
Alentis is a clinical-stage, privately held biotechnology company pioneering first-in-class antibodies and antibody-drug conjugates (ADCs) targeting claudin-1 for fibrosis and oncology indications. Beyond the company’s lead antibody for fibrosis, lixudebart, Alentis is developing oncology candidates ALE.P02 and ALE.P03. These are claudin-1 targeted ADCs with a tubulin inhibitor payload and topoisomerase‑I inhibitor payload, respectively. ALE.P02 was granted Fast Track designation by FDA for the treatment of advanced or metastatic claudin-1 expressing squamous cancers, irrespective of the organ of origin. Both ADCs are currently in Phase 1/2 studies enrolling patients with a variety of solid tumor types.

Alentis was founded on the groundbreaking research in the laboratory of Prof. Thomas Baumert, MD, at the University of Strasbourg and the French National Institute of Health and Medical Research (Inserm). The company is headquartered in Basel, Switzerland. Visit www.alentis.ch

“Future Resonance — ShanghaiEye Night” Brings Shanghai to Washington, Fosters People-to-People Exchange Across the Pacific

WASHINGTON, Oct. 4, 2026 /PRNewswire/ — On October 3, 2026, local time, a Shanghai-themed cultural exchange event was held on the National Mall in Washington, D.C., bringing a taste of Shanghai to the U.S. Titled “Future Resonance — ShanghaiEye Night,” the event was also part of the “Shanghai Let’s Meet” city promotion initiative and a broader series of China-U.S. people-to-people exchanges. Through a variety of cultural activities and interactions, the event built bridges between people across the Pacific and offered a glimpse of Shanghai as an open, inclusive and dynamic international metropolis.

"Future Resonance — ShanghaiEye Night" China-U.S. people-to-people exchange events held in Washington D.C. Photo: Shanghai Media Group
“Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange events held in Washington D.C. Photo: Shanghai Media Group

The event, held by Shanghai Media Group, brought together nearly 100 prominent figures from China and the United States across the political, business, technology, cultural and arts sectors. Song Jiongming, President of Shanghai Media Group, and Susan Lee, Secretary of State of Maryland, attended the event and delivered remarks. Chinese Ambassador to the United States Xie Feng was also in attendance.

In the afternoon, the National Mall was transformed into a “mini Shanghai” carnival. The carnival featured 50 stalls showcasing international cuisine, a “Shanghai Charm” themed exhibition area and displays of China’s intangible cultural heritage.

Visitors got a glimpse of Shanghai’s cutting-edge technological innovation through a model of the C919 passenger jet, explored the city’s latest trends through a model of the Oriental Pearl Tower and popular Chinese cultural and creative IPs, and took a virtual journey through Shanghai’s past and present with VR headsets provided by the Shanghai Museum. Time-honored brands such as White Rabbit candy, Hero fountain pens and Lao Feng Xiang offered visitors a taste of Shanghai’s iconic homegrown brands. Meanwhile, an IP SHANGHAI lenticular art exhibition brought the city to life through dynamic images that changed as visitors moved around the displays.

From such an immersive experience showcasing Shanghai as a first stop for international visitors entering China to distinctive IPs spanning culture, commerce, tourism, sports and exhibitions, the carnival offered Americans and international visitors a glimpse of the city and a chance to experience Shanghai firsthand at one of Washington’s most iconic landmarks. Many visitors said they hoped to visit Shanghai in person and explore the city on foot through a “city walk.”

As the sun began to set, its golden glow fell over the Capitol dome. Against an iconic backdrop featuring the two cities, the “Future Resonance” outdoor concert got underway.

Young performers from China and the United States took the stage alongside renowned artists from both countries. The One Voice Children’s Choir from the United States and the Manhattan Philharmonic joined forces to perform “We Are Together,” a song created in Shanghai to celebrate friendship between the two countries.

The program featured a rich mix of symphonic works, traditional Chinese music, Chinese opera and anime music. Footage from Shanghai’s city image film “UP! SHANGHAI” played on the large screen behind the stage throughout the concert.

Later that evening, nearly 100 guests from China and the United States, including prominent figures from politics, business, technology, culture and the arts, took part in the ShanghaiEye Night dialogue session.

Themed “Invest in China for a Win-Win Future,” the dialogue highlighted the China International Import Expo and Shanghai’s development as an international economic, financial, trade, shipping and technological innovation center. It also showcased the city’s world-class business environment and provided a platform for high-level dialogue and practical cooperation between Chinese and U.S. companies.

The dialogue also featured a “Shanghai Charm” city image reception area. On one side, twenty selected historical photographs capturing key “Shanghai moments” in China-U.S. relations were displayed, including the signing of the Shanghai Communiqué, the launch of the first China-U.S. air route, the opening of Apple’s first store in China, the Tesla Gigafactory and the 10th anniversary of Shanghai Disney Resort.

On the other side, 20 photographs from the IP SHANGHAI platform, under the theme “Chasing Dreams in Shanghai,” showcased Lujiazui Financial City, Yangshan Deep-Water Port, Shanghai Grand Opera House, the North Bund shipping hub, and the Huangpu River and Suzhou Creek. Together, the displays offered guests a visual introduction to the city and created lasting memories of Shanghai.

With the support of the Information Office of the Shanghai Municipal Government and co-hosted by Shanghai Media Group, the World Intangible Cultural Heritage Conservation Center and the Washington Chinese Community Alliance, the event brought together guests from a range of sectors in China and the United States.

The event brought Shanghai closer to American audiences and the international community through city promotion, cultural performances, interactive experiences and high-level dialogue. It also provided a platform for people-to-people and cultural exchange between China and the United States. Reflecting the theme “Future Resonance,” the event hoped to give a warm and positive boost to people-to-people exchanges between the two countries.

Chinese performers present Peking Opera at the “Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange event in Washington, D.C.
Chinese performers present Peking Opera at the “Future Resonance — ShanghaiEye Night” China-U.S. people-to-people exchange event in Washington, D.C.

Dr Maye Musk, author, supermodel, and dietitian, speaks at the Prudential Leadership Forum

Shares perspectives on leadership, resilience and legacy with nearly 1,000 customers, young professionals, and aspiring leaders


HONG KONG SAR – Media OutReach Newswire – 4 October 2026 – Prudential Hong Kong Limited (“Prudential”) welcomed Dr Maye Musk, a globally renowned author, supermodel and dietitian, to the Prudential Leadership Forum, titled Beyond Success: The Blueprint for Leadership, Resilience and Legacy, held on 3 October 2026.

(From left) Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited; Dr Maye Musk; and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc, at the Prudential Leadership Forum, where they shared perspectives on leadership, resilience and legacy planning across generations.
(From left) Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited; Dr Maye Musk; and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc, at the Prudential Leadership Forum, where they shared perspectives on leadership, resilience and legacy planning across generations.

Nearly 1,000 VIP customers, young professionals, aspiring leaders and top-performing financial consultants came together for a conversation on resilience, reinvention and the values that shape lasting family legacies.

Opening the forum, Lawrence Lam, Chief Executive Officer, Prudential Hong Kong Limited, highlighted Prudential’s commitment to customers: “Prudential has earned enduring trust with families by actively listening to their evolving needs across generations. Sustaining that trust requires a forward-looking vision, creating meaningful opportunities for customers to connect with visionary leaders and fresh perspectives. Dr Maye Musk’s journey is a powerful reminder that experience, resilience and ambition can open new possibilities at every stage of life. ”

The centerpiece of the day was an engaging fireside chat between Dr Musk and Angel Ng, Regional CEO, Greater China; Group Customer and Wealth, Prudential plc. Through the exchange, Dr Musk shared candid reflections on rebuilding her career across life stages and countries, empowering her three children to pursue their distinct ambitions, and wealth succession.

Reflecting on her journey, Dr Musk said: “Success is rarely a straight line. Throughout my life, I have had to start over, adapt and embrace new opportunities, often when others thought it was too late. What I have learned is that resilience is built through action, not certainty. Whether as a parent, a professional or a leader, our role is not to create a perfect path for the next generation, but to give them the confidence, values and independence to create their own. Lasting legacies are built not by removing challenges, but by helping others develop the strength to navigate them.”

Angel highlighted Prudential’s vision for legacy: “In today’s rapidly evolving world, planning for the next generation is about more than passing on financial wealth. It is also about passing on the values and judgement that help them make informed decisions and pursue their aspirations. When families pair clear principles with the confidence to make their own choices, they can protect what they have built while creating a stronger foundation for generations to come. Prudential supports families in planning ahead, passing on their wealth with confidence, and building a brighter tomorrow.”

Building on the theme of preparing for the future, the forum then turned to the city’s distinctive advantages and emerging opportunities for talent through a panel discussion titled Hong Kong: Where Global Wealth and Talent Converge. Felix Chan, the Director of Hong Kong Talent Engage; and Jason Fong, Global Head of Family Office at Invest Hong Kong shared perspectives on how the leaders of tomorrow can learn, grow and thrive in Hong Kong.

By bringing together forward-looking perspectives and opportunities to engage with global leaders, Prudential continues to support customers at every stage of life, helping them plan for their health and financial wellbeing, protect what matters most, and build resilience for the future. This commitment is also reflected in value-added platforms such as PruNextGen, through which we support families in planning early for their children’s future, broadening their horizons and laying the foundations for lifelong success.

Hashtag: #PrudentialLeadershipForum

The issuer is solely responsible for the content of this announcement.

About Prudential Hong Kong Limited

Prudential has been serving the people of Hong Kong since 1964. Through Prudential Hong Kong Limited and Prudential General Insurance Hong Kong Limited, the Company provides a range of financial planning services and products, including individual life insurance, investment-linked insurance, retirement solutions, health and medical protection, general insurance, and employee benefits to protect over 1.41 million customers in Hong Kong. Beyond Hong Kong, Prudential serves the Macau community through its branch, offering health insurance and financial solutions to complete its footprint in the Greater Bay Area. Visit for more information.